NEW YORK (GenomeWeb News) – Transgenomic and the Medical College of Wisconsin today announced an agreement under which Transgenomic will offer next-generation sequencing-based testing from the MCW Clinical Sequencing Program.
Services offered under the collaboration will include Transgenomic's NuclearMitome test for mitochondrial disorders. The test uses NGS technology for the identification of 448 genes that are considered important for mitochondrial function, and according to Transgenomic, it represents the most comprehensive genetic test for such disorders. The MCW laboratory will become the first to offer the test.
Financial and other terms of the deal were not disclosed.
"This collaboration allows Transgenomic to rapidly expand the commercial use of our NuclearMitome test in addition to building out our offerings in whole-genome and exome testing," Transgenomc CEO Craig Tuttle said in a statement.
Howard Jacob, director of the Human and Molecular Genetics Center at MCW added, "The ability to evaluate 400-plus genes with one diagnostic tool should shorten patients' diagnostic odysseys and provide faster answers."